Physician profile

Keith Mankowitz

Cardiovascular Disease · Chesterfield, MO

NPI 1598783938

$16,478.87

in general payments reported to CMS, 2019-2025

51 companies · $2,414 in 2025

The $2,414 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,680.30
Education$184.49

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $5,624.03 2019-2024
Novartis Pharmaceuticals Corporation $1,322.31 2019-2025
Regeneron Healthcare Solutions, INC. $1,209.53 2019-2025 Evkeeza, Praluent
Amgen INC. $924.63 2019-2025 Repatha, Repatha
Boston Scientific Corporation $846.68 2019-2025 Watchman Access System, Watchman Flx
Merck Sharp & Dohme LLC $600.20 2021-2025 Verquvo
Janssen Pharmaceuticals, INC $557.28 2019-2024 Xarelto
Astrazeneca Pharmaceuticals Lp $543.36 2020-2025 Farxiga, Andexxa, Wainua
Pfizer INC. $534.35 2019-2025
Novo Nordisk INC $424.61 2023-2025 Ozempic, Rybelsus, Wegovy
Amarin Pharma, INC. $354.24 2019-2022
Esperion Therapeutics, INC. $337.91 2021-2025 Nexletol
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $331.26 2019-2025 Lifevest
E.R. Squibb & Sons, L.L.C. $281.47 2019-2025 Camzyos
Boehringer Ingelheim Pharmaceuticals, INC. $281.34 2019-2025 Jardiance
Show all 51 companies
CompanyGeneral paymentsYearsTop products
Alnylam Pharmaceuticals INC. $217.12 2022-2025 Onpattro
Akcea Therapeutics, INC. $210.35 2019-2021
American Regent $174.60 2025 Injectafer
Heartflow, INC. $171.03 2024-2025
Lundbeck LLC $167.36 2019-2020
Kestra Medical Technology Services, INC. $134.16 2022-2025 Assure Wcd
Bridgebio Pharma, INC. $89.44 2025 Attruby
Kiniksa Pharmaceuticals, Ltd. $82.97 2022-2023 Arcalyst
Cvrx, INC. $82.47 2023-2024 Barostim Neo System
Bayer Healthcare Pharmaceuticals INC. $72.63 2022-2025
Kiniksa Pharmaceuticals International, Plc $71.00 2024 Arcalyst
Impulse Dynamics (USA) INC. $60.25 2022-2024 Optimizer, Optimizer
Philips North America LLC $58.77 2019-2025 (Ck4) Mcot, Ambulatory Monitoring & Diagnostics Undivided
Lilly USA, LLC $57.72 2025 Zepbound, Mounjaro
Preventice Services, LLC $56.61 2019
Abbott Laboratories $53.28 2023 Jot Dx, Confirm Rx
Genzyme Corporation $47.13 2019-2023
Daiichi Sankyo INC. $44.35 2019-2024 Injectafer
Abiomed $41.79 2023 Impella
Edwards Lifesciences Corporation $40.07 2019-2021
Lexicon Pharmaceuticals, INC. $35.25 2023-2024 Inpefa
Scpharmaceuticals INC. $32.99 2024-2025
Azurity Pharmaceuticals, INC. $31.00 2025 Edarbi
Csl Behring $30.97 2022
Kowa Pharmaceuticals America, INC. $25.75 2021-2022
Aegerion Pharmaceuticals, INC. $25.26 2019
Arbor Pharmaceuticals, INC. $23.52 2019-2020
Inari Medical, INC. $21.94 2022
Glaxosmithkline, LLC. $20.71 2025 Arexvy
Zoll Circulation INC $20.47 2025 Downstream Cartridge, Therox Ds2 Console, Catheter
Irhythm Technologies, INC. $20.16 2023 Zio Xt Patch
Vital Connect, INC $20.10 2024 Vitalpatch Rtm
Portola Pharmaceuticals, LLC $18.72 2019
Amryt Pharma Holdings Ltd $17.31 2021
Medicure Pharma INC. $16.79 2023 Zypitamag
Hikma Pharmaceuticals USA $11.63 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Keith Mankowitz

$16,478.87

in general payments reported 2019-2025

Years
2019-2025
Top company
Sanofi-Aventis U.S. LLC
Context
The $2,414 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/1177419/keith-mankowitz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.